Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Allergen (AGN) PT Lowered to $200 at Mizuho Securities
January 30, 2019 8:21 AM ESTMizuho Securities analyst Irina Koffler lowered the price target on Allergen (NYSE: AGN) to $200.00 (from $213.00) while maintaining a Buy rating. Mizuho Securities raised our 2019 revenue from $15.0B to $15.1B due to continued Restasis durability in 1Q:19. Koffler also slightly lowered the tax rate (to... More
Allergan (AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call
January 29, 2019 8:43 AM ESTAllergan (NYSE: AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call
... MoreAllergan (AGN) Tops Q4 EPS by 14c, Offers Q1 and FY Guidance, Approves $2B Buyback
January 29, 2019 7:04 AM EST(Updated - January 29, 2019 7:12 AM EST)
Allergan (NYSE: AGN) reported Q4 EPS of $4.29, $0.14 better than the analyst estimate of $4.15. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4 billion.
GUIDANCE:
Allergan sees FY2019 EPS of at least... More
